Tags

Type your tag names separated by a space and hit enter

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Antivir Ther. 2016; 21(5):455-9.AT

Abstract

Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Kim UJ
Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.
Won EJ
No affiliation info available
Kee SJ
No affiliation info available
Jung SI
No affiliation info available
Jang HC
No affiliation info available

MeSH

Antiviral AgentsCoronavirus InfectionsDrug Therapy, CombinationHumansInterferon-alphaLopinavirMaleMiddle AgedMiddle East Respiratory Syndrome CoronavirusRepublic of KoreaRibavirinRitonavir

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

26492219

Clinical Trial Links

Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients

Citation

Kim, Uh Jin, et al. "Combination Therapy With Lopinavir/ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome." Antiviral Therapy, vol. 21, no. 5, 2016, pp. 455-9.
Kim UJ, Won EJ, Kee SJ, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455-9.
Kim, U. J., Won, E. J., Kee, S. J., Jung, S. I., & Jang, H. C. (2016). Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antiviral Therapy, 21(5), 455-9. https://doi.org/10.3851/IMP3002
Kim UJ, et al. Combination Therapy With Lopinavir/ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome. Antivir Ther. 2016;21(5):455-9. PubMed PMID: 26492219.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. AU - Kim,Uh Jin, AU - Won,Eun-Jeong, AU - Kee,Seung-Jung, AU - Jung,Sook-In, AU - Jang,Hee-Chang, Y1 - 2015/10/22/ PY - 2015/10/11/accepted PY - 2015/10/23/entrez PY - 2015/10/23/pubmed PY - 2018/1/23/medline SP - 455 EP - 9 JF - Antiviral therapy JO - Antivir Ther VL - 21 IS - 5 N2 - Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection. SN - 2040-2058 UR - https://www.unboundmedicine.com/medline/citation/26492219/Combination_therapy_with_lopinavir/ritonavir_ribavirin_and_interferon_α_for_Middle_East_respiratory_syndrome_ DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓122]

Related Citations

More